Mokari Atabak sold $3.5M of CORT

Mokari Atabak (Chief Financial Officer) sold 40,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $87.71 ($86.78–$89.43, $3.51M total) across 4 trades on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mokari Atabak
Published Jul 17, 2026, 10:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 17, 2026, 10:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
high confidence
Mentioned
$CORT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

The disclosed sale amount ($3.51M) and remaining holdings (16,130 shares) may slightly influence sentiment, but the 10b5-1 plan reduces interpretive weight.

02

Market read

Traders may monitor for clustering of insider activity, but this specific disclosure adds limited new fundamental information.

03

What to watch

The article does not disclose whether other insiders sold/bought around the same time, nor does it provide post-sale performance context beyond remaining shares.

Relevance 5/10Novelty 3/10Timing: after-hours, filed July 17 for a July 15 sale

Background

The article is an SEC Form 4 insider transaction for Corcept Therapeutics, reported by the CFO.

Company-level read

Ticker impact

$CORTNeutralHigh confidence
Context

Corcept Therapeutics CFO Mokari Atabak sold about $3.51M of CORT shares via an open-market sale under a 10b5-1 plan.

Expected impact

Likely minimal price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new operating, regulatory, or financial guidance.

Market effects

No clear sector read-through; this is company-specific insider trading data.

None.

None.

Counterpoint

10b5-1 sales are often scheduled and not necessarily bearish; the sale may reflect diversification or liquidity needs rather than outlook.

Key entities

  • Corcept Therapeutics

    Company whose shares were sold by its CFO under a 10b5-1 plan.

  • Mokari Atabak

    Chief Financial Officer who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.